Nutrient induced type 2 and chemical induced type 1 experimental diabetes differently modulate gastric GLP-1 receptor expression

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Bloch, Olga ^a   Broide, Efrat ^a   Ben Yehudah, Gilad ^a   Cantrell, Dror ^a   Shirin, Haim ^a   Rapoport, Micha J ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INSULIN; MESSENGER RNA; STREPTOZOCIN; GLUCAGON LIKE PEPTIDE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE DIET; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HOUSEKEEPING GENE; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSAMMOMYS OBESUS; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH MUCOSA; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; EXPERIMENTAL DIABETES MELLITUS; GASTRIC MUCOSA; GERBIL; METABOLISM; PANCREAS; SPRAGUE DAWLEY RAT; STOMACH;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FEMALE; GASTRIC MUCOSA; GERBILLINAE; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; PANCREAS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; STOMACH; STREPTOZOCIN;

EID: 84928253268     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/561353     Document Type: Article

References (35)

1. J. J. Holst, "Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1," Diabetes/Metabolism Research and Reviews, vol. 18, no. 6, pp. 430-441, 2002.
2. L. Vedtofte, D. P. Sonne, J. J. Holst, and F. K. Knop, "The extrapancreatic effect of GLP-1," International Diabetes Monitor, vol. 22, pp. 196-202, 2010.
3. U. Kielgast, T. Krarup, J. J. Holst, and S. Madsbad, "Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual-cell function," Diabetes Care, vol. 34, no. 7, pp. 1463-1468, 2011.
4. A. Varanasi,N. Bellini,D. Rawal et al., "Liraglutide as additional treatment for type 1 diabetes," European Journal of Endocrinology, vol. 165, no. 1, pp. 77-84, 2011.
5. L. B. Harrison, P. F. Mora, G. O. Clark, and I. Lingvay, "Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs," Journal of Investigative Medicine, vol. 61, no. 1, pp. 40-44, 2013.
6. J. Unger, "Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes," Current Diabetes Reports, vol. 13, no. 5, pp. 663-668, 2013.
7. E. Broide, O. Bloch, G. Ben-Yehudah, D. Cantrell, H. Shirin, and M. J. Rapoport, "GLP-1 receptor is expressed in human stomach mucosa: analysis of its cellular association and distribution within gastric glands," Journal of Histochemistry & Cytochemistry, vol. 61, no. 9, pp. 649-658, 2013.
8. E. Broide, O. Bloch, G. Ben-Yehudah, D. Cantrell,H. Shirin, and M. J. Rapoport, "Reduced GLP-1R expression in gastric glands of patients with type 2 diabetes mellitus," Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 9, pp. E1691-E1695, 2014.
9. G. Xu, H. Kaneto, D. R. Laybutt et al., "Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes," Diabetes, vol. 56, no. 6, pp. 1551-1558, 2007.
10. A. J. F. King, "The use of animal models in diabetes research," British Journal of Pharmacology, vol. 166, no. 3, pp. 877-894, 2012.
11. R. K. Selvaraju, I. Velikyan, L. Johansson et al., "In vivo imaging of the glucagonlike peptide 1 receptor in the pancreas with 68Ga-labeled DO3A-exendin-4," Journal of Nuclear Medicine, vol. 54, no. 8, pp. 1458-1463, 2013.
12. D. R. Laybutt, M. Glandt, G. Xu et al., "Critical reduction-cell mass results in two distinct outcomes over time. Adaptation with impaired glucose tolerance or decompensated diabetes," The Journal of Biological Chemistry, vol. 278, no. 5, pp. 2997-3005, 2003.
13. C. O. Eleazu, K. C. Eleazu, S. Chukwuma, and U. N. Essien, "Review of the mechanism of cell death resulting from streptozotocin challenge in experimental animals, its practical use and potential risk to humans," Journal of Diabetes & Metabolic Disorders, vol. 12, no. 1, pp. 60-67, 2013.
14. P. Piyachaturawat, J. Poprasit, T. Glinsukon, and C. Wanichanon, "Gastric mucosal lesions in streptozotocin-diabetic rats," Cell Biology International Reports, vol. 12, no. 1, pp. 53-63, 1988.
15. W. F. Lam, A. A. M. Masclee, E. S. M. Muller, and C. B. H. W. Lamers, "Effect of hyperglycemia on gastric acid secretion during the gastric phase of digestion," The American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 272, no. 5, pp. G1116-G1121, 1997.
16. S. M. A. Bastaki, E. Adeghate, I. S. Chandranath et al., "Effects of streptozotocin-induced long-term diabetes on parietal cell function and morphology in rats," Molecular and Cellular Biochemistry, vol. 341, no. 1-2, pp. 43-50, 2010.
17. K. Takeuchi, K. Ueshima, T. Ohuchi, and S. Okabe, "Induction of gastric lesions and hypoglycemic response by food deprivation in streptozotocin-diabetic rats," Digestive Diseases and Sciences, vol. 39, no. 3, pp. 626-634, 1994.
18. D. J. O'Halloran, G. C. Nikou, B. Kreymann, M. A. Ghatei, and S. R. Bloom, "Glucagon-like peptide-1 (7-36)-NH2: a physiological inhibitor of gastric acid secretion in man," Journal of Endocrinology, vol. 126, no. 1, pp. 169-173, 1990.
19. X. Jia, J. C. Brown, Y. N. Kwok, R. A. Pederson, and C. H. S. McIntosh, "Gastric Inhibitory polypeptide and glucagon-like peptide-1 (7-36) amide exert Similar effects on somatostatin secretion but opposite effects on gastrin secretion from the rat stomach," Canadian Journal of Physiology and Pharmacology, vol. 72, no. 10, pp. 1215-1219, 1994.
20. R. Eissele, H. Koop, and R. Arnold, "Effect of glucagon-like peptide-1 on gastric somatostatin and gastrin secretion in the rat," Scandinavian Journal of Gastroenterology, vol. 25, no. 5, pp. 449-454, 1990.
21. G. Leibowitz, S. Ferber, ?A. Apelqvist et al., "IPF1/PDX1 deficiency and beta-cell dysfunction in Psammomys obesus, with type 2 diabetes," Diabetes, vol. 50, no. 8, pp. 1799-1806, 2001.
22. N. Kaiser, R. Nesher, M. Y. Donath et al., "Psammomys obesus, a model for environment-gene interactions in type 2 diabetes," Diabetes, vol. 54, supplement 2, pp. S137-S144, 2005.
23. A. M. K. Hansen, T. B. Bödvarsdottir, D. N. E. Nordestgaard et al., "Upregulation of alpha cell glucagon-like peptide 1 (GLP-1) in Psammomys obesus-an adaptive response to hyperglycaemia" Diabetologia, vol. 54, no. 6, pp. 1379-1387, 2011.
24. L. Ahlkvist, K. Brown, and B. Ahrén, "Upregulated insulin secretion in insulin-resistant mice: evidence of increased islet GLP1 receptor levels and GPR119-activated GLP1 secretion," Endocrine Connections, vol. 2, no. 2, pp. 69-78, 2013.
25. T. B. Bödvarsdóttir, K. D. Hove, C. F. Gotfredsen et al., "Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes," Diabetologia, vol. 53, no. 10, pp. 2220-2223, 2010.
26. Y. Nie, M. Nakashima, P. L. Brubaker et al., "Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats," The Journal of Clinical Investigation, vol. 105, no. 7, pp. 955-965, 2000.
27. S. Thyssen, E. Arany, andD. J. Hill, "Ontogenyof regenerationof ?-cells in the neonatal rat after treatment with streptozotocin," Endocrinology, vol. 147, no. 5, pp. 2346-2356, 2006.
28. P. D. Cani, C. A. Daubioul, B. Reusens, C. Remacle, G. Catillon, and N. M. Delzenne, "Involvement of endogenous glucagon-like peptide-1 (7-36) amide on glycaemia-lowering effect of oligofructose in streptozotocin-treated rats," Journal of Endocrinology, vol. 185, no. 3, pp. 457-465, 2005.
29. G. E. Lim, G. J. Huang, N. Flora, D. Leroith, C. J. Rhodes, and P. L. Brubaker, "Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell," Endocrinology, vol. 150, no. 2, pp. 580-591, 2009.
30. F. Zhang, X. Tang, H. Cao et al., "Impaired secretion of total glucagon-like peptide-1 in people with impaired fasting glucose combined impaired glucose tolerance," International Journal of Medical Sciences, vol. 9, no. 7, pp. 574-581, 2012.
31. W. O. C. Creutzfeldt, N. Kleine, B. Willms, C. Ørskov, J. J. Holst, and M. A. Nauck, "Glucagonostatic actions reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients," Diabetes Care, vol. 19, no. 6, pp. 580-586, 1996.
32. U. Kielgast, J. J. Holst, and S. Madsbad, "Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists," Current Diabetes Reviews, vol. 5, no. 4, pp. 266-275, 2009.
33. C. Koliaki and J. Doupis, "Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus," DiabetesTherapy, vol. 2, no. 2, pp. 101-121, 2011.
34. U. Kielgast, J. J. Holst, and S. Madsbad, "Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual-cell function," Diabetes, vol. 60, no. 5, pp. 1599-1607, 2011.
35. J. J. Holst, "The physiology of glucagon-like peptide 1," Physiological Reviews, vol. 87, no. 4, pp. 1409-1439, 2007.